Chinese drug manufacturer Yichang HEC Changjiang Pharmaceutical launched an initial public offering in Hong Kong on Monday at a time investors are highly selective in taking on healthcare-related assets.
A termsheet seen by FinanceAsia shows the company is selling 90.1 million shares, or 20% of its enlarged share capital, at an indicative price range of HK$13.70-HK$18.50 per share at the base size. There is a standard 15% greenshoe option.
At this range, the company is valued at 13.6x-18.4x consensus analyst earnings estimates for next year on a pre-shoe basis, or 14.0x-19.0x on a post-shoe basis.
The deal was launched as China’s...